Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Breast Cancer

  Free Subscription


Articles published in BMJ

Retrieve available abstracts of 39 articles:
HTML format



Single Articles


    February 2024
  1. FREEMAN K, Jenkinson D, Clements K, Wallis MG, et al
    Atypia detected during breast screening and subsequent development of cancer: observational analysis of the Sloane atypia prospective cohort in England.
    BMJ. 2024;384:e077039.
    PubMed     Abstract available


    January 2024
  2. MANNU GS, Wang Z, Dodwell D, Broggio J, et al
    Invasive breast cancer and breast cancer death after non-screen detected ductal carcinoma in situ from 1990 to 2018 in England: population based cohort study.
    BMJ. 2024;384:e075498.
    PubMed     Abstract available


  3. SCHMIDT MK, Lips EH, Schmitz RS, Verschuur E, et al
    Invasive breast cancer and breast cancer death after non-screen detected ductal carcinoma in situ.
    BMJ. 2024;384:q22.
    PubMed    


  4. SARKAR S
    How patriarchy and conservatism fuel deadly hesitancy among women with breast cancer.
    BMJ. 2024;384:p2563.
    PubMed    


    November 2023
  5. WEAVER N
    We must remove access barriers to endocrine drugs for breast cancer prevention.
    BMJ. 2023;383:p2709.
    PubMed    



  6. Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial.
    BMJ. 2023;383:p2665.
    PubMed    


  7. MAHASE E
    Anastrozole: Repurposed drug could prevent thousands of breast cancer cases.
    BMJ. 2023;383:p2608.
    PubMed    


    October 2023
  8. MA F, Yan M, Li W, Ouyang Q, et al
    Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial.
    BMJ. 2023;383:e076065.
    PubMed     Abstract available


  9. SCHMITZ RSJM, van den Belt-Dusebout AW, Clements K, Ren Y, et al
    Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort study.
    BMJ. 2023;383:e076022.
    PubMed     Abstract available


    September 2023
  10. DAVIES EA, Wang YH
    Understanding inequalities in breast cancer screening uptake.
    BMJ. 2023;382:p2084.
    PubMed    


  11. HOFVIND S, Iqbal N, Thy JE, Mangerud G, et al
    Effect of invitation letter in language of origin on screening attendance: randomised controlled trial in BreastScreen Norway.
    BMJ. 2023;382:e075465.
    PubMed     Abstract available


  12. CATHCART-RAKE EJ, Tevaarwerk AJ, Haddad TC, D'Andre SD, et al
    Advances in the care of breast cancer survivors.
    BMJ. 2023;382:e071565.
    PubMed     Abstract available


  13. OKE JL, Welch HG
    Breast cancer: conflating case fatality with mortality.
    BMJ. 2023;382:p2086.
    PubMed    


    August 2023
  14. MAHASE E
    Breast cancer screening: Overdiagnosis increases significantly with age, researchers say.
    BMJ. 2023;382:p1823.
    PubMed    


    July 2023

  15. Breast cancer mortality in 500 000 women with early invasive breast cancer in England, 1993-2015: population based observational cohort study.
    BMJ. 2023;382:p1744.
    PubMed    


    June 2023
  16. TAYLOR C, McGale P, Probert J, Broggio J, et al
    Breast cancer mortality in 500 000 women with early invasive breast cancer in England, 1993-2015: population based observational cohort study.
    BMJ. 2023;381:e074684.
    PubMed     Abstract available


  17. MACKENZIE M, Stobart H, Dodwell D, Taylor C, et al
    Risk of breast cancer death after a diagnosis of early invasive breast cancer.
    BMJ. 2023;381:p1355.
    PubMed    


  18. KIRBY AM, Holt F, Taylor CW, Haviland JS, et al
    Should patients requiring radiotherapy for breast cancer be treated with proton beam therapy?
    BMJ. 2023;381:e072896.
    PubMed    


    May 2023
  19. LEON-FERRE RA, Goetz MP
    Advances in systemic therapies for triple negative breast cancer.
    BMJ. 2023;381:e071674.
    PubMed     Abstract available


  20. TANNE JH
    Breast cancer: US recommends women start screening at 40.
    BMJ. 2023;381:1077.
    PubMed    


  21. CLIFT AK, Dodwell D, Lord S, Petrou S, et al
    Development and internal-external validation of statistical and machine learning models for breast cancer prognostication: cohort study.
    BMJ. 2023;381:e073800.
    PubMed     Abstract available


    April 2023
  22. GATHANI T, Cutress R, Horgan K, Kirwan C, et al
    Age and sex can predict cancer risk in people referred with breast symptoms.
    BMJ. 2023;381:e073269.
    PubMed    


    March 2023
  23. FLEMING B, Edison P, Kenny L
    Cognitive impairment after cancer treatment: mechanisms, clinical characterization, and management.
    BMJ. 2023;380:e071726.
    PubMed     Abstract available


    February 2023
  24. BERDZULI N
    Breast cancer: from awareness to access.
    BMJ. 2023;380:290.
    PubMed    


    January 2023
  25. LIMB M
    Black women in England are at greater risk of late cancer diagnosis than white women.
    BMJ. 2023;380:211.
    PubMed    


    September 2022
  26. BUNDRED JR, Michael S, Stuart B, Cutress RI, et al
    Margin status and survival outcomes after breast cancer conservation surgery: prospectively registered systematic review and meta-analysis.
    BMJ. 2022;378:e070346.
    PubMed     Abstract available


  27. BUNDRED NJ, Bundred JR, Cutress RI, Dodwell D, et al
    Width of excision margins after breast conserving surgery for invasive breast cancer and distant recurrence and survival.
    BMJ. 2022;378:o2077.
    PubMed    


    July 2022
  28. MENKES DB, Hoeh NR
    Doctor-patient relationship is essential to curtail overdiagnosis.
    BMJ. 2022;378:o1750.
    PubMed    


  29. WISE J
    NICE approves two more treatment options for advanced breast cancer.
    BMJ. 2022;378:o1751.
    PubMed    


    June 2022
  30. IACOBUCCI G
    NICE recommends new targeted treatment for early breast cancer.
    BMJ. 2022;377:o1491.
    PubMed    


  31. PAPAUTSKY EL
    A full time job: a year with early-stage breast cancer.
    BMJ. 2022;377:o1421.
    PubMed    


    May 2022
  32. WISE J
    NICE allows immunotherapy treatment for small group of patients with advanced triple negative breast cancer.
    BMJ. 2022;377:o1311.
    PubMed    


  33. WISE J
    Breast cancer: NICE recommends innovative magnetic technology for locating sentinel lymph nodes.
    BMJ. 2022;377:o1226.
    PubMed    


    March 2022
  34. SAUL H, Gursul D, Cassidy S, Vinogradova Y, et al
    Risk of breast cancer with HRT depends on therapy type and duration.
    BMJ. 2022;376:o485.
    PubMed     Abstract available


  35. TANNE JH
    Breast cancer is overdiagnosed in one in six or seven cases, finds large US study.
    BMJ. 2022;376:o581.
    PubMed    


    January 2022
  36. BARTHOLOMEW T, Colleoni M, Schmidt H
    Financial incentives for breast cancer screening undermine informed choice.
    BMJ. 2022;376:e065726.
    PubMed    


    December 2021
  37. CONFORTI F, Pala L, Sala I, Oriecuia C, et al
    Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis.
    BMJ. 2021;375:e066381.
    PubMed     Abstract available


  38. KRZYZANOWSKA MK, Julian JA, Gu CS, Powis M, et al
    Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial.
    BMJ. 2021;375:e066588.
    PubMed     Abstract available


    November 2021
  39. BRUCE J, Mazuquin B, Canaway A, Hossain A, et al
    Exercise versus usual care after non-reconstructive breast cancer surgery (UK PROSPER): multicentre randomised controlled trial and economic evaluation.
    BMJ. 2021;375:e066542.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.